Corina Taitt

I spent more than 20 years in global pharmaceutical leadership driving clinical development strategy, organizational transformation, patient safety, and regulatory execution across oncology and specialty medicine portfolios.
Combines deep clinical expertise with broad end-to-end drug development experience spanning protocol design, medical monitoring, clinical trial execution, benefit-risk assessment, safety governance, regulatory submissions, labeling strategy, health authority interactions, commercial launch readiness, and post-marketing lifecycle management.

Contributed to development and approval strategies supporting multiple oncology products including Enhertu, Datroway, Opdivo (nivolumab), and Yervoy (ipilimumab). Known for building high-performing organizations, aligning complex stakeholder groups, and driving transformational change across matrix environments.